YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

Boston Scientific Taxus Stent


AddThis Social Bookmark Button

Boston Scientific Taxus Stent

The Boston Scientific Taxus Express Stent was approved in March 2004 and has made the company into the largest coronary stent manufacturer in the U.S.  The stent emits paclitaxel, a drug intended to inhibit restenosis caused by scar tissue growth.  The stent uses a proprietary polymer, Translute™, to control the release of the drug paclitaxel.  In late November 2006, a new meta analysis by the Cleveland Clinic of 14 studies of drug coated heart stents found that the incidence of blood clots with these newer devices is four to five times the incidence associated with the original metal stents which eluted no drugs.  Because of the increased risk of thrombosis and resulting heart attacks, patients with the paclitaxel-eluting Boston Scientific Taxus stent are required to take anti-clotting medications for six months or more.  If you or a loved one have a Taxus stent and have suffered clotting as a result, contact Parker & Waichman, LLP for a free legal case consultation.  Call 1-800-LAW-INFO (1-800-529-4636) or fill out the form at the right for legal assistance.

Taxus Stent Recalls
Boston Scientific Corp., the largest maker of heart stents, has had multiple voluntary recalls of its drug-coated Taxus devices because of defects in the delivery system. About 200 Taxus stents were recalled in July 2004. After identifying further problems, the company recalled 85,000 Taxus stents (both drug coated and bare metal types) later that month.  In August 2004, an additional 3,000 Taxus stents were recalled that had been manufacturered prior to the aforementioned recalls.  The catheter problems appear to have been caused when too much heat was applied during the laser welding stage in the manufacturing process, the company said.

If you or a loved one suffered injuries from a Boston Scientific Taxus stent, please fill out the form at the right for a free case evaluation by a qualified defective medical device attorney.
Boston Scientific Taxus StentRSS Feed

Efficacy of heart stents called into question

Mar 27, 2007 | Financial Times
A seven-year US study has called into question whether doctors are overusing heart stents, the blockbuster tiny wire mesh tubes used to prop open narrowing coronary arteries. The results of the study, called Courage, added more uncertainty to a stent market that recently has been thrown into flux over questions of safety, appropriate usage and new competition. This flux was also highlighted by a 7 per cent fall in the share price of Boston Scientific, a leading US stent maker, because new...

Angioplasty no better than drugs, study says

Mar 27, 2007 | Boston Globe
A large and long-awaited study finds that angioplasty works no better than medication at preventing heart attacks or death, a finding that could slow the growth of one of medicine's most common cardiac interventions. The research comes on the heels of a growing debate over whether some patients are getting unnecessary angioplasty, a procedure that involves using a tiny balloon and metal scaffolds called stents to prop open clogged arteries. Angioplasty is recommended for those with fully...

Study: Heart Stents Often Not Worth the Risk or Cost

Mar 27, 2007 | NewsInferno.com
A highly anticipated new study has called into question the long-term effectiveness of stents in the treatment of stable coronary artery disease. Researchers have determined that the use of drug therapy (including blood-pressure and cholesterol drugs) is just as effective in preventing heart attacks or death when compared to a combination of drug therapy and stent implantation. The study results were shared this week at the American College of Cardiology’s (ACC) annual Scientific Session...

Heart Stents No Better Than Treating Stable Heart Patients With Medication, Study Shows

Mar 26, 2007 | Washington Post
The study of more than 2,000 patients found that those who underwent the expensive procedure, known as angioplasty, in non-emergency situations were no less likely to suffer a heart attack or die than those who only took aspirin and other medicines to thin their blood and lower blood pressure and cholesterol, along with adopting life style changes. The study is the first large, well-designed comparison of angioplasty to non-surgical care for patients who are not actually having heart attack or...

Heart stent makers brace for new heart study

Mar 26, 2007 | AP
Wall Street analysts and many doctors expect another potential setback for makers of stents when results of a blockbuster study Tuesday will answer whether an artery-opening procedure plus drugs is better than medication alone for lower-risk heart patients with chest pain. It's the first big study to directly compare angioplasty procedures with drug therapy alone as a way to prevent heart attacks and deaths in non-emergency cases. If the research reaches the conclusion many analysts and...

More Boston Scientific Taxus Stent News

Boston Scientific Taxus Stent
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date the device was implanted:

Is the device still implanted?


What medical condition prompted the use of the device?

Please describe any problems or injuries caused by the device:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News